ClinicalTrials.Veeva

Menu

Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease (LUNGSCLEROCT)

C

Central Hospital, Nancy, France

Status

Enrolling

Conditions

Systemic Sclerosis
Interstitial Lung Disease

Study type

Observational

Funder types

Other

Identifiers

NCT05482607
2022PI105

Details and patient eligibility

About

Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of mortality. SSc-ILD is variable: from limited forms (with asymptomatic patients) to extensive lesions. Disease course in SSc-ILD is also highly variable: patients can experience stable disease, slow or fast progression. Investigators performed unsupervised clustering analysis to classify SSc-ILD according to elementary radiological lesions on HRCT scan.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with systemic sclerosis according to 2013 ACR/EULAR criteria
  • Patients with interstitial lung disease on HRCT chest

Exclusion criteria

  • Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)

Trial design

100 participants in 1 patient group

SSc-ILD patients

Trial contacts and locations

1

Loading...

Central trial contact

Paul DECKER, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems